3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
58
Breast Neoplasms
25
Neoplasms
5
Neoplasm Metastasis
3
Leiomyoma
3
Polycystic Ovary Syndrome
2
Neoplasms by Site
2
Endometrial Neoplasms
2
Cardiovascular Diseases
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Ovarian Neoplasms
1
Osteoporosis
1
Oligometastatic Prostate Carcinoma
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Kallmann Syndrome
1
Inflammatory Breast Neoplasms
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Breast Neoplasms
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT02221999
2023-08-29
SHPD002
RenJi Hospital
Phase 2/3
Active not recruiting
250 enrolled